跳至主要内容
临床试验/NCT06594822
NCT06594822已完成3 期

Effectiveness of Probiotics and Standard Therapy Versus Standard Therapy Alone in Patients of Mild to Moderate Rheumatoid Arthritis

King Edward Medical University1 个研究点 分布在 1 个国家目标入组 88 人开始时间: 2023年8月24日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
88
试验地点
1
主要终点
Disease Activity Score (DAS-28) score

研究概览

简要总结

To assess the effectiveness of probiotics when given in combination with standard therapy in patients of mild to moderate rheumatoid arthritis

详细描述

This study was conducted on the patients presenting to the Rheumatology out-patients department of the Department of Medicine, King Edward Medical University, Mayo hospital, Lahore from 24th August, 2023 till 23rd February, 2024. A total of 88 patients of either sex, between the age group of 18 to 70 years and having an established diagnosis of rheumatoid arthritis (RA), [as proved on history, X-rays and biologic markers like Rheumatoid Factor (RF) and Anti-cyclic citrullinated protein antibodies (anti-CCP antibodies), Erythrocyte Sedimentation Rate (ESR) and C- reactive protein (CRP)] and having mild to moderate disease activity score (DAS-28 score between 2.6 to <5.1) were selected via simple random sampling.

After approval from the Board of Studies (BOS) and Advanced Study Research Board (ASRB) of King Edward Medical University, Mayo Hospital, Lahore, all patients conforming to the selection criteria were enrolled in the study. Informed written and verbal consent was taken from all the participants. Patient's demographic data was obtained and recorded in a predesigned proforma. Patients were divided into two groups by computer generated method. Group A comprised 44 patients who received standard therapy [analgesics, glucocorticoids, any Disease modifying anti-rheumatic drug (DMARD)] alongwith probiotic (Bacillus clausii), whereas Group B also comprising 44 patients received standard therapy alone. Lab investigations like complete blood counts (CBC), C- reactive protein (CRP), liver function tests (LFTs) and renal function tests (RFTs) were done at baseline and then on follow up visits at 45 and 90 days. Disease activity score (DAS-28) was assessed on baseline then on each subsequent visit to monitor response to treatment. Mild RA patients had a DAS-28 score between 2.6 to 3.1 and moderate RA patients had a DAS-28 score between 3.1 to <5.1. Effectiveness was defined in terms of reduction of DAS-28 score of ≥0.6 from the baseline based on European League against Rheumatism (EULAR) response rates. Pancytopenia, derangement in LFTs and RFTs twice from the baseline as a result of treatment resulted in exclusion from the study.

Data was analyzed using computer software Statistical Package for Social Sciences (SPSS) version 26.0. Quantitative variables like age, DAS-28 score were expressed as mean and standard deviation (Mean±SD). Qualitative variables including gender were expressed as frequency and percentages. Chi- square test was used to compare response between the two groups. P value ≤0.05 was considered statistically significant.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1- Patients of either sex. 2- Patients between the age group of 18 to 70 years. 3- Patients having an established diagnosis of rheumatoid arthritis (proven on history, X-rays and biologic markers like RF and Anti-CCP antibodies, ESR and CRP).
  • 4- Patients having mild to moderate disease activity (DAS-28 score between 2.6 to <5.1).

排除标准

  • 1- Patients treated previously for RA with probiotics. 2- Patients with a history of allergy to probiotics. 3- Patients with mixed connective tissue disorder and overlap syndrome as per history and labs.
  • 4- Patients with a history of gastrectomy, renal failure and liver cirrhosis. 5- Patients with recent or current use of antibiotics. 6- Pregnant patients and lactating mothers.

结局指标

主要结局

Disease Activity Score (DAS-28) score

时间窗: 3 months

Reduction in DAS-28 score of ≥ 0.6 from the baseline. (Mild RA baseline score between 2.6 - 3.1, Moderate RA baseline score between 3.1 to \<5.1)

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Fawad Ahmad Randhawa

Associate Professor of Endocrinology

King Edward Medical University

研究点 (1)

Loading locations...

相似试验